Overview

• Amansa acquired 51.60 lakh equity shares from General Atlantic at ₹484.47 apiece, lowering General Atlantic’s stake to 54.01%.
• The board sanctioned the transaction after consulting Axis Capital, IIFL Capital, JM Financial and SBI Capital Markets as book running lead managers.
• Rubicon’s draft red herring prospectus will see its fresh issue trimmed from ₹500 crore to ₹250 crore, with the offer-for-sale component unchanged.
• The company highlights its R&D-driven model targeting regulated markets, featuring 69 US FDA–approved products and US FDA- and Health Canada-inspected facilities.
• Final IPO dates, prospectus details and listing schedule are pending as Rubicon plans to use proceeds for debt repayment, inorganic growth and corporate purposes.